A case of diabetes secondary to treatment with protease inhibitors

Authors

  • Sandra Bento Interna do Internato Complementar de Oncologia Médica, Serviço de Oncologia Médica I do Instituto Português de Oncologia de Francisco Gentil
  • Fausto Roxo Assistente Hospitalar de Medicina lnterna, Serviço de Medicina I do Hospital Distrital de Santarém
  • Cristina Esteves Assistente Hospitalar de Medicina lnterna, Serviço de Medicina I do Hospital Distrital de Santarém
  • Victor Bezerra Assistente Hospitalar Graduado de Medicina Interna, Serviço de Medicina I do Hospital Distrital de Santarém
  • Manuel Gomes Chefe de Serviço de Medicina lnterna, Serviço de Medicina I do Hospital Distrital de Santarém

Keywords:

AIDS, diabetes, protease inhibitors

Abstract

The authors report a case of diabetes ín a patíent receíving protease inihibitors (saquinavir) for the treatment of Human Immunodefícíency Vírus (HIV).

A 39 year-old male, positive for the HIV antibody since 1991 and havíng AIDS sínce 1994, developed resístance to combínatíon therapy wíth zidovudine, zalcitabine and ritonavír. He began therapy wíth saquinavir, showíig progessive clinical improvement, but developed type 2 diabetes.

Downloads

Download data is not yet available.

References

Carpenler CCJ, et al. Antiretroviral therapy in HIV infection 1996. JAMA 1996; 276: 146-154.

Roche. lnvirase (Saquinavir) product monograph

Drug evaluations: ritonavir. Micromedex, inc vol.95

Drug evaluations: saquinavir. Micromedex, inc. vol. 95

Aull A. FDA warns of potential protease inhibitor link to hyperglycemia

Dubé MP. Johnson DL et ai. Protease inhibitor associated hyperglycemia. Lancet 1997; 350 : 713-714

Public health advisory on protease inhibitors for HIV trea1me111 JAMA 1997; 278: 379.

Lumpkin MM. Reports of diabetes anel hyperglycemia in patients receiving protease inhibitors for the treatment of HIV. Public health advisory 1997.

Inibidores da protease, hiperglicémia e diabetes mellitus. Boletim de Farmacovigilância 1997: 1: 3.

Therapeutic products directorate of health Canada. reports of diabetes in patients receiving protease inhibitors for treatment of HIV. July 1997.

HIV guidelines co-ordinating committee. British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 618: 943-964.

Mnyle GJ. Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice. Esp Opin Drugs 1997; 618: 943-964

Additional Files

Published

2000-06-30

How to Cite

1.
Bento S, Roxo F, Esteves C, Bezerra V, Gomes M. A case of diabetes secondary to treatment with protease inhibitors. RPMI [Internet]. 2000 Jun. 30 [cited 2024 Nov. 21];7(2):82-4. Available from: https://revista.spmi.pt/index.php/rpmi/article/view/1982

Issue

Vol. 7 No. 2 (2000): Abril/ Junho

Section

Case Reports

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Medicina Interna

Open Access

Most read articles by the same author(s)